You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 81 - 90 of 6207 results
  1. Protein depleting pre-existing antibodies for viral gene therapy

    SBC: NEUROGT INC            Topic: NIAID

    Project Summary: This is a fast-track SBIR grant proposal. As effective gene therapy (GT) products using adeno-associated viral (AAV) vectors advance to clinical applications, the translation faces critical challenge of high prevalence of αAA) antibodies (Abs) in humans. Currently, only individuals negative of αAAV-Abs are eligible for AAV GT treatment. The goal of this SBIR project is to develo ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients

    SBC: Allander Biotechnologies            Topic: NIDCR

    Summary Oral mucositis, a severe oral ulceration, is a common toxic effect of radio- or chemoradio-therapy (RT or CRT) and a limiting factor to using the optimal dose of radiation for effective cancer treatment. Intensity modulated RT (IMRT) and stereotactic Body RT (SBRT) spare more normal tissues and lessen chronic side effects, but not oral mucosa in head and neck cancer patients. To date, Pali ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Unique Antimicrobial Vascular Catheter to Prevent Catheter-Related Blood Stream Infections (CRBSI)

    SBC: Brighton Development            Topic: NHLBI

    Abstract The goal of this Phase I effort is determine the feasibility of developing a unique antimicrobial catheter to reduce the instances of one of the most prevalent healthcare associated infection, Catheter-Related Blood Stream Infection (CRBSI). This research and development effort will be to develop an intravascular catheter with inherent long lasting antiseptic properties to protect the pat ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of anticoagulant sulfated glycans

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: 300

    Sulfated glycan 8-mer is a carbohydrate-based compound with anticoagulant activity. The goal of this project is to replace animal-sourced low-molecular weight heparin (LMWH) with the 8- mer. LMWHs are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US, which ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Mission Empower

    SBC: ROCK BY ROCK LLC            Topic: NIGMS

    Project Summary: Mission Empower: Health According to the Society of Public Health Education, only 7.5% of K-5 schools nationally provide sufficient health education (Society for Public Health Education, 2017). IDM and game-based learning strategies have the potential to help close this gap but, to date, most public health solutions have not been scalable (Zamboni, et al 2019). Too often IDM and h ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959

    SBC: T3D Therapeutics, Inc.            Topic: NIA

    T3D-959 is a new chemical entity, orally delivered, small molecule, dual nuclear receptor agonist aimed at improving dysfunctional brain glucose energy and lipid metabolism in Alzheimer’s disease (AD), it is non- amyloid/non-tau-directed. Metabolic homeostasis, inherently altered in AD, leads to protein misfolding resulting in plaque formation, tangle formation and inflammation. Exploratory huma ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A next generation cross-serotype binding antitoxin for treatment of post-exposure botulinum poisoning

    SBC: NIGHTHAWK BIOSCIENCES, INC.            Topic: NIAID

    PROJECT SUMMARY Botulinum poisoning is a rare neurotoxin-mediated syndrome that results in progressive respiratory and muscular paralysis and leads to death if untreated. Aerosolized botulinum neurotoxins (BoNT) are particularly lethal and of major concern as potential biological weapons. Given this concern, the U.S. has stockpiled the only approved antidote for BoNT poisoning, BAT®, to be used i ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform

    SBC: ISABL INC.            Topic: NCI

    Project Summary Isabl Inc. is a Memorial Sloan Kettering Cancer Center spin out, aiming to launch a cancer whole genome and transcriptome sequencing (cWGTS) diagnostic test for pediatric and rare cancer patients. The product of this SBIR is Isabl GxT, a precision medicine platform that incorporates cWGTS data into a robust data science framework to enable clinically actionable reporting in a clini ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Innovative Sorbents for Stabilizing Per- and Polyfluoroalky Substances (PFAS) in Soil Contaminated by Aqueous Film-forming Foam (AFFF)

    SBC: Regenerative Solutions, Inc.            Topic: NIEHS

    Project Summary/Abstract: Per- and polyfluoroalkyl substances (PFAS) are a group of chemicals consisting of thousands of synthetic organic compounds in which the hydrogen atoms bound to the carbon backbones are fully or partially substituted with fluorine. Due to their widespread use, PFAS are detected ubiquitously. Owing to the nature of PFAS being persistent, bioaccumulative, and toxic, cleaning ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter

    SBC: Halomine Inc.            Topic: 400

    Abstract: Catheter-associated urinary tract infection (CAUTI) is the most common type of healthcare-associated infection, however currently there is no effective technology to address the problem. Antimicrobial (anti-biofilm) functionality on the catheter surface is an important field that has gained a lot of attention; however, commercial applications are limited due to a lack of infection contro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government